Wolverine Legal Status, FDA 503A Category, and Compounding Access

Where access is heading — and where it stands today

Wolverine legal status starts with momentum. Access to the blend's component peptides is under active FDA review, and it may expand in 2026. The anchor for that statement is a scheduled event on FDA's own public calendar: an FDA Pharmacy Compounding Advisory Committee (PCAC) meeting is scheduled for July 23-24, 2026 to discuss these peptides as candidates for inclusion on the 503A bulks list ^[12]. That is the forward-leaning, evidence-anchored fact — a scheduled discussion of substances under evaluation.

The present-tense fact is more restrictive, and it is stated plainly. Both components of the Wolverine blend — BPC-157 and TB-500 — are currently research peptides that FDA placed in its 503A "Category 2": bulk substances FDA identified as potentially presenting significant safety risks. That placement took effect with the September 29, 2023 update to FDA's list of nominated bulk drug substances ^[10]. Category 2 substances are not within FDA's enforcement-discretion policy for 503A compounding, so compounding-pharmacy access is currently restricted ^[11].

Nothing here states a reclassification as done, dated, or certain. The July 2026 meeting is a scheduled, advisory discussion — not a decision, and not a listing ^[12]. Whether access expands, and when, is not established. This page is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance.

What FDA 503A Category 2 means for the blend

Compounding in the United States runs on two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight and FDA registration and inspection ^[11].

A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet on a bulks list are evaluated by FDA through a public nomination process, with input from the PCAC ^[11].

Under FDA's interim policy, nominated substances were sorted into categories. Category 1 substances may be eligible for the bulks list and are covered by FDA's enforcement-discretion policy while under evaluation. Category 2 substances are those FDA identified as raising significant safety risks; they are not covered by that policy, and FDA stated it would consider taking action against a compounder using a Category 2 substance ^[11]. For BPC-157 and TB-500, FDA cited concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[10].

What is the FDA 503A status of Wolverine?

The blend is not an approved drug. Both of its components are in FDA's 503A Category 2: FDA placed BPC-157, and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," on its list of bulk substances that may present significant safety risks, effective with the September 29, 2023 update ^[10]. Both are also on the published agenda of the July 23-24, 2026 PCAC meeting as candidates being considered for the 503A bulks list — a scheduled evaluation, not a change in current status ^[12].

Both components are on the same scheduled review

There is no component carve-out in the Wolverine blend. Both BPC-157 and TB-500 are currently Category 2, and both are on one scheduled FDA review.

BPC-157 — listed by FDA as "BPC-157 (free base)" and "BPC-157 acetate" — appears on the published agenda of the PCAC meeting scheduled for July 23-24, 2026, as a substance being considered for inclusion on the 503A bulks list ^[12]. TB-500 — the Ac-LKKTETQ fragment of Thymosin Beta-4, listed as "TB-500 (free base)" and "TB-500 acetate" — appears on the same agenda, as a substance being considered for inclusion on the 503A bulks list ^[12].

Being discussed by the PCAC is a step in evaluation, not a final listing decision ^[11]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by the committee's input. So both halves of the blend are currently restricted, both are under the same scheduled review, and neither outcome is established or dated ^[12].

Can you get BPC-157 from a compounding pharmacy?

Under current FDA status, routine 503A pharmacy compounding of BPC-157 is restricted: FDA placed it in Category 2, outside the enforcement-discretion policy, effective with the September 29, 2023 list update ^[10]. BPC-157 is on the PCAC agenda for July 23-24, 2026 as a bulks-list candidate, but that is a scheduled discussion, not a change in current status, and no outcome should be assumed ^[12].

How legally compounded peptide access works

Where a peptide is eligible to be compounded, lawful access in the United States follows one general pathway. A compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber — in person or via a compliant telehealth encounter — who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription ^[11].

From there, the prescription is dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility ^[11]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It is a route to a licensed-prescriber consultation, not a separate legal status: telehealth does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate prescriber-patient relationship and a valid prescription ^[11].

The ingredient-eligibility caveat is the part that currently binds the Wolverine blend. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules — a USP/NF monograph, a component of an approved drug, or a place on the applicable FDA bulks list. Ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[11]. Today, that describes both BPC-157 and TB-500 ^[10]. This page names no specific pharmacy, clinic, telehealth provider, or vendor; gives no dosing or administration instructions; and is general information about the regulatory landscape rather than medical or legal advice.

FDA approval and WADA status

Two further status questions recur for the blend, alongside the compounding-eligibility question above.

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use, and the blend has no approved indication. In the United States, FDA placed both components in its 503A Category 2 of bulk substances flagged for significant safety risks, effective with the September 29, 2023 update ^[10]. Both are also prohibited by the World Anti-Doping Agency: BPC-157 under the S0 non-approved-substances category, and TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories.

Is Wolverine legal?

Status depends on jurisdiction and context. Neither constituent is an FDA-approved medicine, and the blend has no approved indication. In the U.S. compounding framework, both components are currently 503A Category 2 bulk substances, which restricts pharmacy compounding access while that status stands ^{[10] [11]}. Both are also WADA-prohibited in sport. Research-use and human-use contexts are treated differently, and this is general regulatory information, not legal advice.

The chemical identity behind TB-500's regulatory standing is well established: it is the synthetic N-terminal acetylated 17-23 fragment of thymosin beta-4 (Ac-LKKTETQ), characterized in the analytical literature for doping-control reference ^{[5] [6]} — the same fragment that appears under "TB-500" on FDA's Category 2 list and on the July 2026 PCAC agenda ^{[10] [12]}.